Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients

Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients - Saccharated ferric oxide and FGF23

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004814

Enrollment

Registered

2011-01-03

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients with iron-deficiency anemia

Interventions

saccharated ferric oxide dosage

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The dialysis outpatient who takes less than Hb 10.5g/dl, less than Ferritin 100 ng/ml, 3 times a week dialysis and more than three months in a dialysis carrer.

Exclusion criteria

Exclusion criteria: exclude a patient with menstruation, active gastrointestinal hemorrhage, tumor-bearing, hematological disorder, hepatitis and liver cirrhosis, secondary hyperparathyroidism (intact parathyroid hormon more than 500 pg/ml), parathyroidectomy.

Design outcomes

Primary

Measure	Time frame
Evaluation of FGF23, and Mineral metabolism	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026